References
- Aerts, J.M., Ottenhoff, R., Powlson, A.S., Grefhorst, A., van Eijk, M., Dubbelhuis, P.F., Aten, J., Kuipers, F., Serlie, M.J., Wennekes, T., et al. (2007). Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. Diabetes 56, 1341-1349. https://doi.org/10.2337/db06-1619
- Al Fadel, F., Fayyaz, S., Japtok, L., and Kleuser, B. (2016). Involvement of sphingosine 1-phosphate in palmitate-induced non-alcoholic fatty liver disease. Cell. Physiol. Biochem. 40, 1637-1645. https://doi.org/10.1159/000453213
- Barr, E.L., Cameron, A.J., Balkau, B., Zimmet, P.Z., Welborn, T.A., Tonkin, A.M., and Shaw, J.E. (2010). HOMA insulin sensitivity index and the risk of all-cause mortality and cardiovascular disease events in the general population: the Australian Diabetes, Obesity and Lifestyle Study (AusDiab) study. Diabetologia 53, 79-88. https://doi.org/10.1007/s00125-009-1588-0
- Bashiardes, S., Shapiro, H., Rozin, S., Shibolet, O., and Elinav, E. (2016). Nonalcoholic fatty liver and the gut microbiota. Mol. Metab. 5, 782-794. https://doi.org/10.1016/j.molmet.2016.06.003
- Bataller, R. and Brenner, D.A. (2005). Liver fibrosis. J. Clin. Invest. 115, 209-218. https://doi.org/10.1172/JCI24282
- Becker, S., Kinny-Koster, B., Bartels, M., Scholz, M., Seehofer, D., Berg, T., Engelmann, C., Thiery, J., Ceglarek, U., and Kaiser, T. (2017). Low sphingosine-1-phosphate plasma levels are predictive for increased mortality in patients with liver cirrhosis. PLoS One 12, e0174424. https://doi.org/10.1371/journal.pone.0174424
- Bissell, D.M. (1998). Hepatic fibrosis as wound repair: a progress report. J. Gastroenterol. 33, 295-302. https://doi.org/10.1007/s005350050087
- Bradbury, M.W. (2006). Lipid metabolism and liver inflammation. I. Hepatic fatty acid uptake: possible role in steatosis. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G194-G198. https://doi.org/10.1152/ajpgi.00413.2005
- Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., Aradhye, S., and Burtin, P. (2010). Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9, 883-897. https://doi.org/10.1038/nrd3248
- Brunati, A.M., Tibaldi, E., Carraro, A., Gringeri, E., D'Amico, F., Jr, Toninello, A., Massimino, M.L., Pagano, M.A., Nalesso, G., and Cillo, U. (2008). Crosstalk between PDGF and S1P signalling elucidates the inhibitory effect and potential antifibrotic action of the immunomodulator FTY720 in activated HSC-cultures. Biochim. Biophys. Acta 1783, 347-359. https://doi.org/10.1016/j.bbamcr.2007.11.008
- Chang, N., Ge, J., Xiu, L., Zhao, Z., Duan, X., Tian, L., Xie, J., Yang, L., and Li, L. (2017). HuR mediates motility of human bone marrow-derived mesenchymal stem cells triggered by sphingosine 1-phosphate in liver fibrosis. J. Mol. Med. 95, 69-82. https://doi.org/10.1007/s00109-016-1460-x
- Chaurasia, B., Tippetts, T.S., Mayoral Monibas, R., Liu, J., Li, Y., Wang, L., Wilkerson, J.L., Sweeney, C.R., Pereira, R.F., et al. (2019). Targeting a ceramide double bond improves insulin resistance and hepatic steatosis. Science 365, 386-392. https://doi.org/10.1126/science.aav3722
-
Chen, J., Wang, W., Qi, Y., Kaczorowski, D., McCaughan, G.W., Gamble, J.R., Don, A.S., Gao, X., Vadas, M.A., and Xia, P. (2016a). Deletion of sphingosine kinase 1 ameliorates hepatic steatosis in diet-induced obese mice: role of
$PPAR\gamma$ . Biochim. Biophys. Acta 1861, 138-147. https://doi.org/10.1016/j.bbalip.2015.11.006 - Chen, Q., Denard, B., Lee, C.E., Han, S., Ye, J.S., and Ye, J. (2016b). Inverting the topology of a transmembrane protein by regulating the translocation of the first transmembrane helix. Mol. Cell 63, 567-578. https://doi.org/10.1016/j.molcel.2016.06.032
- Chen, T.C., Lee, R.A., Tsai, S.L., Kanamaluru, D., Gray, N.E., Yiv, N., Cheang, R.T., Tan, J.H., Lee, J.Y., Fitch, M.D., et al. (2019). An ANGPTL4-ceramideprotein kinase Czeta axis mediates chronic glucocorticoid exposureinduced hepatic steatosis and hypertriglyceridemia in mice. J. Biol. Chem. 294, 9213-9224. https://doi.org/10.1074/jbc.RA118.006259
- Cohen, J.C., Horton, J.D., and Hobbs, H.H. (2011). Human fatty liver disease: old questions and new insights. Science 332, 1519-1523. https://doi.org/10.1126/science.1204265
- Deevska, G.M., Rozenova, K.A., Giltiay, N.V., Chambers, M.A., White, J., Boyanovsky, B.B., Wei, J., Daugherty, A., Smart, E.J., Reid, M.B., et al. (2009). Acid sphingomyelinase deficiency prevents diet-induced hepatic triacylglycerol accumulation and hyperglycemia in mice. J. Biol. Chem. 284, 8359-8368. https://doi.org/10.1074/jbc.M807800200
- Denard, B., Lee, C., and Ye, J. (2012). Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1. Elife 1, e00090. https://doi.org/10.7554/eLife.00090
- Ding, B.S., Liu, C.H., Sun, Y., Chen, Y., Swendeman, S.L., Jung, B., Chavez, D., Cao, Z., Christoffersen, C., Nielsen, L.B., et al. (2016). HDL activation of endothelial sphingosine-1-phosphate receptor-1 (S1P1) promotes regeneration and suppresses fibrosis in the liver. JCI Insight 1, e87058.
- Dyckman, A.J. (2017). Modulators of sphingosine-1-phosphate pathway biology: recent advances of sphingosine-1-phosphate receptor 1 (S1P1) agonists and future perspectives. J. Med. Chem. 60, 5267-5289. https://doi.org/10.1021/acs.jmedchem.6b01575
- Friedman, S.L. (2008). Mechanisms of hepatic fibrogenesis. Gastroenterology 134, 1655-1669. https://doi.org/10.1053/j.gastro.2008.03.003
- Fucho, R., Martinez, L., Baulies, A., Torres, S., Tarrats, N., Fernandez, A., Ribas, V., Astudillo, A.M., Balsinde, J., Garcia-Roves, P., et al. (2014). ASMase regulates autophagy and lysosomal membrane permeabilization and its inhibition prevents early stage non-alcoholic steatohepatitis. J. Hepatol. 61, 1126-1134. https://doi.org/10.1016/j.jhep.2014.06.009
- Gao, D., Pararasa, C., Dunston, C.R., Bailey, C.J., and Griffiths, H.R. (2012). Palmitate promotes monocyte atherogenicity via de novo ceramide synthesis. Free Radic. Biol. Med. 53, 796-806. https://doi.org/10.1016/j.freeradbiomed.2012.05.026
-
Gao, W., Liu, H., Yuan, J., Wu, C., Huang, D., Ma, Y., Zhu, J., Ma, L., Guo, J., Shi, H., et al. (2016). Exosomes derived from mature dendritic cells increase endothelial inflammation and atherosclerosis via membrane TNF-
$\alpha$ mediated NF-$\kappa$ B pathway. J. Cell. Mol. Med. 20, 2318-2327. https://doi.org/10.1111/jcmm.12923 - Geng, T., Sutter, A., Harland, M.D., Law, B.A., Ross, J.S., Lewin, D., Palanisamy, A., Russo, S.B., Chavin, K.D., and Cowart, L.A. (2015). SphK1 mediates hepatic inflammation in a mouse model of NASH induced by high saturated fat feeding and initiates proinflammatory signaling in hepatocytes. J. Lipid Res. 56, 2359-2371. https://doi.org/10.1194/jlr.M063511
- Gonzalez-Fernandez, B., Sanchez, D.I., Crespo, I., San-Miguel, B., Alvarez, M., Tunon, M.J., and Gonzalez-Gallego, J. (2017). Inhibition of the SphK1/ S1P signaling pathway by melatonin in mice with liver fibrosis and human hepatic stellate cells. BioFactors 43, 272-282. https://doi.org/10.1002/biof.1342
- Gosejacob, D., Jäger, P.S., Vom Dorp, K., Frejno, M., Carstensen, A.C., Köhnke, M., Degen, J., Dörmann, P., and Hoch, M. (2016). Ceramide synthase 5 is essential to maintain C16:0-ceramide pools and contributes to the development of diet-induced obesity. J. Biol. Chem. 291, 6989-7003. https://doi.org/10.1074/jbc.M115.691212
- Hajduch, E., Balendran, A., Batty, I.H., Litherland, G.J., Blair, A.S., Downes, C.P., and Hundal, H.S. (2001). Ceramide impairs the insulin-dependent membrane recruitment of protein kinase B leading to a loss in downstream signalling in L6 skeletal muscle cells. Diabetologia 44, 173-183. https://doi.org/10.1007/s001250051596
- Hastie, C.E., Padmanabhan, S., Slack, R., Pell, A.C., Oldroyd, K.G., Flapan, A.D., Jennings, K.P., Irving, J., Eteiba, H., Dominiczak, A.F., et al. (2010). Obesity paradox in a cohort of 4880 consecutive patients undergoing percutaneous coronary intervention. Eur. Heart J. 31, 222-226. https://doi.org/10.1093/eurheartj/ehp317
- Higuchi, H. and Gores, G.J. (2003). Mechanisms of liver injury: an overview. Curr. Mol. Med. 3, 483-490. https://doi.org/10.2174/1566524033479528
- Holland, W.L., Brozinick, J.T., Wang, L.P., Hawkins, E.D., Sargent, K.M., Liu, Y., Narra, K., Hoehn, K.L., Knotts, T.A., Siesky, A., et al. (2007). Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab. 5, 167-179. https://doi.org/10.1016/j.cmet.2007.01.002
- Ichi, I., Nakahara, K., Fujii, K., Iida, C., Miyashita, Y., and Kojo, S. (2007). Increase of ceramide in the liver and plasma after carbon tetrachloride intoxication in the rat. J. Nutr. Sci. Vitaminol. 53, 53-56. https://doi.org/10.3177/jnsv.53.53
- Ikeda, H., Watanabe, N., Ishii, I., Shimosawa, T., Kume, Y., Tomiya, T., Inoue, Y., Nishikawa, T., Ohtomo, N., Tanoue, Y., et al. (2009). Sphingosine 1-phosphate regulates regeneration and fibrosis after liver injury via sphingosine 1-phosphate receptor 2. J. Lipid Res. 50, 556-564. https://doi.org/10.1194/jlr.M800496-JLR200
- Jiang, C., Xie, C., Li, F., Zhang, L., Nichols, R.G., Krausz, K.W., Cai, J., Qi, Y., Fang, Z.Z., Takahashi, S., et al. (2015). Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J. Clin. Invest. 125, 386-402. https://doi.org/10.1172/JCI76738
- Jiang, M., Li, C., Liu, Q., Wang, A., and Lei, M. (2019). Inhibiting ceramide synthesis attenuates hepatic steatosis and fibrosis in rats with nonalcoholic fatty liver disease. Front. Endocrinol. 10, 665. https://doi.org/10.3389/fendo.2019.00665
- Jin, J., Zhang, X., Lu, Z., Perry, D.M., Li, Y., Russo, S.B., Cowart, L.A., Hannun, Y.A., and Huang, Y. (2013). Acid sphingomyelinase plays a key role in palmitic acid-amplified inflammatory signaling triggered by lipopolysaccharide at low concentrations in macrophages. Am. J. Physiol. Endocrinol. Metab. 305, E853-E867. https://doi.org/10.1152/ajpendo.00251.2013
- Kageyama, Y., Ikeda, H., Watanabe, N., Nagamine, M., Kusumoto, Y., Yashiro, M., Satoh, Y., Shimosawa, T., Shinozaki, K., Tomiya, T., et al. (2012). Antagonism of sphingosine 1-phosphate receptor 2 causes a selective reduction of portal vein pressure in bile duct-ligated rodents. Hepatology 56, 1427-1438. https://doi.org/10.1002/hep.25780
- Kaneko, T., Murakami, T., Kawana, H., Takahashi, M., Yasue, T., and Kobayashi, E. (2006). Sphingosine-1-phosphate receptor agonists suppress concanavalin A-induced hepatic injury in mice. Biochem. Biophys. Res. Commun. 345, 85-92. https://doi.org/10.1016/j.bbrc.2006.04.067
- Khattar, M., Deng, R., Kahan, B.D., Schroder, P.M., Phan, T., Rutzky, L.P., and Stepkowski, S.M. (2013). Novel sphingosine-1-phosphate receptor modulator KRP203 combined with locally delivered regulatory T cells induces permanent acceptance of pancreatic islet allografts. Transplantation 95, 919-927. https://doi.org/10.1097/TP.0b013e3182842396
- Kim, Y.R., Lee, E.J., Shin, K.O., Kim, M.H., Pewzner-Jung, Y., Lee, Y.M., Park, J.W., Futerman, A.H., and Park, W.J. (2019). Hepatic triglyceride accumulation via endoplasmic reticulum stress-induced SREBP-1 activation is regulated by ceramide synthases. Exp. Mol. Med. 51, 1-16.
- King, A., Houlihan, D.D., Kavanagh, D., Haldar, D., Luu, N., Owen, A., Suresh, S., Than, N.N., Reynolds, G., Penny, J., et al. (2017). Sphingosine-1-phosphate prevents egress of hematopoietic stem cells from liver to reduce fibrosis. Gastroenterology 153, 233-248.e16. https://doi.org/10.1053/j.gastro.2017.03.022
- Kisseleva, T., Cong, M., Paik, Y., Scholten, D., Jiang, C., Benner, C., Iwaisako, K., Moore-Morris, T., Scott, B., Tsukamoto, H., et al. (2012). Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc. Natl. Acad. Sci. U. S. A. 109, 9448-9453. https://doi.org/10.1073/pnas.1201840109
- Kitatani, K., Taniguchi, M., and Okazaki, T. (2015). Role of sphingolipids and metabolizing enzymes in hematological malignancies. Mol. Cells 38, 482-495. https://doi.org/10.14348/molcells.2015.0118
- Kong, Y., Wang, H., Wang, S., and Tang, N. (2014). FTY720, a sphingosine-1 phosphate receptor modulator, improves liver fibrosis in a mouse model by impairing the motility of bone marrow-derived mesenchymal stem cells. Inflammation 37, 1326-1336. https://doi.org/10.1007/s10753-014-9877-2
- Kowalski, G.M., Kloehn, J., Burch, M.L., Selathurai, A., Hamley, S., Bayol, S.A.M., Lamon, S., Watt, M.J., Lee-Young, R.S., McConville, M.J., et al. (2015). Overexpression of sphingosine kinase 1 in liver reduces triglyceride content in mice fed a low but not high-fat diet. Biochim. Biophys. Acta 1851, 210-219. https://doi.org/10.1016/j.bbalip.2014.12.002
- Kurek, K., Piotrowska, D.M., Wiesiolek, P., Lukaszuk, B., Chabowski, A., Gorski, J., and Zendzian-Piotrowska, M. (2013). Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease. Liver Int. 34, 1074-1083. https://doi.org/10.1111/liv.12331
- Lallemand, T., Rouahi, M., Swiader, A., Grazide, M.H., Geoffre, N., Alayrac, P., Recazens, E., Coste, A., Salvayre, R., Negre-Salvayre, A., et al. (2018). nSMase2 (type 2-neutral sphingomyelinase) deficiency or inhibition by GW4869 reduces inflammation and atherosclerosis in Apoe-/- mice. Arterioscler. Thromb. Vasc. Biol. 38, 1479-1492. https://doi.org/10.1161/ATVBAHA.118.311208
- Lee, S.Y., Hong, I.K., Kim, B.R., Shim, S.M., Lee, J.S., Lee, H.Y., Choi, C.S., Kim, B.K., and Park, T.S. (2015). Activation of sphingosine kinase 2 by endoplasmic reticulum stress ameliorates hepatic steatosis and insulin resistance in mice. Hepatology 62, 135-146. https://doi.org/10.1002/hep.27804
- Li, C., Jiang, X., Yang, L., Liu, X., Yue, S., and Li, L. (2009a). Involvement of sphingosine 1-phosphate (SIP)/S1P3 signaling in cholestasis-induced liver fibrosis. Am. J. Pathol. 175, 1464-1472. https://doi.org/10.2353/ajpath.2009.090037
- Li, C., Kong, Y., Wang, H., Wang, S., Yu, H., Liu, X., Yang, L., Jiang, X., Li, L., and Li, L. (2009b). Homing of bone marrow mesenchymal stem cells mediated by sphingosine 1-phosphate contributes to liver fibrosis. J. Hepatol. 50, 1174-1183. https://doi.org/10.1016/j.jhep.2009.01.028
- Li, C., Zheng, S., You, H., Liu, X., Lin, M., Yang, L., and Li, L. (2011). Sphingosine 1-phosphate (S1P)/S1P receptors are involved in human liver fibrosis by action on hepatic myofibroblasts motility. J. Hepatol. 54, 1205-1213. https://doi.org/10.1016/j.jhep.2010.08.028
-
Li, Y., Dong, J., Ding, T., Kuo, M.S., Cao, G., Jiang, X.C., and Li, Z. (2013). Sphingomyelin synthase 2 activity and liver steatosis: an effect of ceramide-mediated peroxisome proliferator-activated receptor
$\gamma$ 2 suppression. Arterioscler. Thromb. Vasc. Biol. 33, 1513-1520. https://doi.org/10.1161/ATVBAHA.113.301498 - Liangpunsakul, S., Rahmini, Y., Ross, R.A., Zhao, Z., Xu, Y., and Crabb, D.W. (2012). Imipramine blocks ethanol-induced ASMase activation, ceramide generation, and PP2A activation, and ameliorates hepatic steatosis in ethanol-fed mice. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G515-G523. https://doi.org/10.1152/ajpgi.00455.2011
- Lindenmeyer, C.C. and McCullough, A.J. (2018). The natural history of nonalcoholic fatty liver disease-an evolving view. Clin. Liver Dis. 22, 11-21. https://doi.org/10.1016/j.cld.2017.08.003
- Liu, X., Yue, S., Li, C., Yang, L., You, H., and Li, L. (2011). Essential roles of sphingosine 1-phosphate receptor types 1 and 3 in human hepatic stellate cells motility and activation. J. Cell. Physiol. 226, 2370-2377. https://doi.org/10.1002/jcp.22572
- Longato, L., Tong, M., Wands, J.R., and de la Monte, S.M. (2012). High fat diet induced hepatic steatosis and insulin resistance: role of dysregulated ceramide metabolism. Hepatol. Res. 42, 412-427. https://doi.org/10.1111/j.1872-034X.2011.00934.x
- Ma, M.M., Chen, J.L., Wang, G.G., Wang, H., Lu, Y., Li, J.F., Yi, J., Yuan, Y.J., Zhang, Q.W., Mi, J., et al. (2007). Sphingosine kinase 1 participates in insulin signalling and regulates glucose metabolism and homeostasis in KK/Ay diabetic mice. Diabetologia 50, 891-900. https://doi.org/10.1007/s00125-006-0589-5
- Maceyka, M., Harikumar, K.B., Milstien, S., and Spiegel, S. (2012). Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 22, 50-60. https://doi.org/10.1016/j.tcb.2011.09.003
- Maceyka, M. and Spiegel, S. (2014). Sphingolipid metabolites in inflammatory disease. Nature 510, 58-67. https://doi.org/10.1038/nature13475
- Mari, M., Colell, A., Morales, A., Caballero, F., Moles, A., Fernandez, A., Terrones, O., Basanez, G., Antonsson, B., Garcia-Ruiz, C., et al. (2008). Mechanism of mitochondrial glutathione-dependent hepatocellular susceptibility to TNF despite NF-kappaB activation. Gastroenterology 134, 1507-1520. https://doi.org/10.1053/j.gastro.2008.01.073
- Mauer, A.S., Hirsova, P., Maiers, J.L., Shah, V.H., and Malhi, H. (2017). Inhibition of sphingosine 1-phosphate signaling ameliorates murine nonalcoholic steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 312, G300-G313. https://doi.org/10.1152/ajpgi.00222.2016
- Merrill, A.H., Jr. (2002). De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway. J. Biol. Chem. 277, 25843-25846. https://doi.org/10.1074/jbc.R200009200
- Mitsutake, S., Zama, K., Yokota, H., Yoshida, T., Tanaka, M., Mitsui, M., Ikawa, M., Okabe, M., Tanaka, Y., Yamashita, T., et al. (2011). Dynamic modification of sphingomyelin in lipid microdomains controls development of obesity, fatty liver, and type 2 diabetes. J. Biol. Chem. 286, 28544-28555. https://doi.org/10.1074/jbc.M111.255646
- Moles, A., Tarrats, N., Morales, A., Dominguez, M., Bataller, R., Caballeria, J., Garcia-Ruiz, C., Fernandez-Checa, J.C., and Mari, M. (2010). Acidic sphingomyelinase controls hepatic stellate cell activation and in vivo liver fibrogenesis. Am. J. Pathol. 177, 1214-1224. https://doi.org/10.2353/ajpath.2010.091257
- Nagahashi, M., Takabe, K., Liu, R., Peng, K., Wang, X., Wang, Y., Hait, N.C., Wang, X., Allegood, J.C., Yamada, A., et al. (2015). Conjugated bile acidactivated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression. Hepatology 61, 1216-1226. https://doi.org/10.1002/hep.27592
- Nishi, T., Kobayashi, N., Hisano, Y., Kawahara, A., and Yamaguchi, A. (2014). Molecular and physiological functions of sphingosine 1-phosphate transporters. Biochim. Biophys. Acta 1841, 759-765. https://doi.org/10.1016/j.bbalip.2013.07.012
- Park, S.J. and Im, D.S. (2017). Sphingosine 1-phosphate receptor modulators and drug discovery. Biomol. Ther. 25, 80-90. https://doi.org/10.4062/biomolther.2016.160
- Park, W.J., Park, J.W., Merrill, A.H., Storch, J., Pewzner-Jung, Y., and Futerman, A.H. (2014). Hepatic fatty acid uptake is regulated by the sphingolipid acyl chain length. Biochim. Biophys. Acta 1841, 1754-1766. https://doi.org/10.1016/j.bbalip.2014.09.009
- Pessayre, D., Mansouri, A., and Fromenty, B. (2002). Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 282, G193-G199. https://doi.org/10.1152/ajpgi.00426.2001
- Postic, C. and Girard, J. (2008). Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J. Clin. Invest. 118, 829-838. https://doi.org/10.1172/JCI34275
- Powell, D.J., Hajduch, E., Kular, G., and Hundal, H.S. (2003). Ceramide disables 3-phosphoinositide binding to the pleckstrin homology domain of protein kinase B (PKB)/Akt by a PKCzeta-dependent mechanism. Mol. Cell. Biol. 23, 7794-7808. https://doi.org/10.1128/MCB.23.21.7794-7808.2003
- Pyne, N.J. and Pyne, S. (2010). Sphingosine 1-phosphate and cancer. Nat. Rev. Cancer 10, 489-503. https://doi.org/10.1038/nrc2875
-
Qi, Y., Chen, J., Lay, A., Don, A., Vadas, M., and Xia, P. (2013). Loss of sphingosine kinase 1 predisposes to the onset of diabetes via promoting pancreatic
$\beta$ -cell death in diet-induced obese mice. FASEB J. 27, 4294-4304. https://doi.org/10.1096/fj.13-230052 -
Raichur, S., Wang, S.T., Chan, P.W., Li, Y., Ching, J., Chaurasia, B., Dogra, S., Ohman, M.K., Takeda, K., Sugii, S., et al. (2014). CerS2 haploinsufficiency inhibits
$\beta$ -Oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. Cell Metab. 20, 687-695. https://doi.org/10.1016/j.cmet.2014.09.015 - Rinella, M.E. and Sanyal, A.J. (2016). Management of NAFLD: a stagebased approach. Nat. Rev. Gastroenterol. Hepatol. 13, 196-205. https://doi.org/10.1038/nrgastro.2016.3
- Rippe, R.A. and Brenner, D.A. (2004). From quiescence to activation: gene regulation in hepatic stellate cells. Gastroenterology 127, 1260-1262. https://doi.org/10.1053/j.gastro.2004.08.028
- Rohrbach, T., Maceyka, M., and Spiegel, S. (2017). Sphingosine kinase and sphingosine-1-phosphate in liver pathobiology. Crit. Rev. Biochem. Mol. Biol. 52, 543-553. https://doi.org/10.1080/10409238.2017.1337706
- Rohrbach, T.D., Asgharpour, A., Maczis, M.A., Montefusco, D., Cowart, L.A., Bedossa, P., Sanyal, A.J., and Spiegel, S. (2019). FTY720/fingolimod decreases hepatic steatosis and expression of fatty acid synthase in dietinduced nonalcoholic fatty liver disease in mice. J. Lipid Res. 60, 1311-1322. https://doi.org/10.1194/jlr.M093799
- Rutkute, K., Asmis, R.H., and Nikolova-Karakashian, M.N. (2007a). Regulation of neutral sphingomyelinase-2 by GSH: a new insight to the role of oxidative stress in aging-associated inflammation. J. Lipid Res. 48, 2443-2452. https://doi.org/10.1194/jlr.M700227-JLR200
- Rutkute, K., Karakashian, A.A., Giltiay, N.V., Dobierzewska, A., and Nikolova-Karakashian, M.N. (2007b). Aging in rat causes hepatic hyperresposiveness to interleukin-1beta which is mediated by neutral sphingomyelinase-2. Hepatology 46, 1166-1176. https://doi.org/10.1002/hep.21777
- Samad, F., Hester, K.D., Yang, G., Hannun, Y.A., and Bielawski, J. (2006). Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk. Diabetes 55, 2579-2587. https://doi.org/10.2337/db06-0330
- Sanyal, A.J. and Pacana, T. (2015). A lipidomic readout of disease progression in a diet-induced mouse model of nonalcoholic fatty liver disease. Trans. Am. Clin. Climatol. Assoc. 126, 271-288.
- Sato, M., Ikeda, H., Uranbileg, B., Kurano, M., Saigusa, D., Aoki, J., Maki, H., Kudo, H., Hasegawa, K., Kokudo, N., et al. (2016). Sphingosine kinase-1, S1P transporter spinster homolog 2 and S1P2 mRNA expressions are increased in liver with advanced fibrosis in human. Sci. Rep. 6, 32119. https://doi.org/10.1038/srep32119
- Sattar, N., Forrest, E., and Preiss, D. (2014). Non-alcoholic fatty liver disease. BMJ 349, g4596. https://doi.org/10.1136/bmj.g4596
- Schilling, J.D., Machkovech, H.M., He, L., Sidhu, R., Fujiwara, H., Weber, K., Ory, D.S., and Schaffer, J.E. (2013). Palmitate and lipopolysaccharide trigger synergistic ceramide production in primary macrophages. J. Biol. Chem. 288, 2923-2932. https://doi.org/10.1074/jbc.M112.419978
- Schuppan, D. and Afdhal, N.H. (2008). Liver cirrhosis. Lancet 371, 838-851. https://doi.org/10.1016/S0140-6736(08)60383-9
- Schwalm, S., Pfeilschifter, J., and Huwiler, A. (2013). Sphingosine-1-phosphate: a Janus-faced mediator of fibrotic diseases. Biochim. Biophys. Acta 1831, 239-250. https://doi.org/10.1016/j.bbalip.2012.07.022
- Shea, B.S. and Tager, A.M. (2012). Sphingolipid regulation of tissue fibrosis. Open Rheumatol. J. 6, 123-129. https://doi.org/10.2174/1874312901206010123
- Stoffel, W., Jenke, B., Holz, B., Binczek, E., Gunter, R.H., Knifka, J., Koebke, J., and Niehoff, A. (2007). Neutral sphingomyelinase (SMPD3) deficiency causes a novel form of chondrodysplasia and dwarfism that is rescued by Col2A1-driven smpd3 transgene expression. Am. J. Pathol. 171, 153-161. https://doi.org/10.2353/ajpath.2007.061285
- Summers, S.A., Garza, L.A., Zhou, H., and Birnbaum, M.J. (1998). Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide. Mol. Cell. Biol. 18, 5457-5464. https://doi.org/10.1128/MCB.18.9.5457
- Tagami, S., Inokuchi Ji, J., Kabayama, K., Yoshimura, H., Kitamura, F., Uemura, S., Ogawa, C., Ishii, A., Saito, M., Ohtsuka, Y., et al. (2002). Ganglioside GM3 participates in the pathological conditions of insulin resistance. J. Biol. Chem. 277, 3085-3092. https://doi.org/10.1074/jbc.M103705200
- Takabe, K. and Spiegel, S. (2014). Export of sphingosine-1-phosphate and cancer progression. J. Lipid Res. 55, 1839-1846. https://doi.org/10.1194/jlr.R046656
- Taniguchi, C.M., Kondo, T., Sajan, M., Luo, J., Bronson, R., Asano, T., Farese, R., Cantley, L.C., and Kahn, C.R. (2006). Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta. Cell Metab. 3, 343-353. https://doi.org/10.1016/j.cmet.2006.04.005
- Turner, N., Kowalski, G.M., Leslie, S.J., Risis, S., Yang, C., Lee-Young, R.S., Babb, J.R., Meikle, P.J., Lancaster, G.I., Henstridge, D.C., et al. (2013). Distinct patterns of tissue-specific lipid accumulation during the induction of insulin resistance in mice by high-fat feeding. Diabetologia 56, 1638-1648. https://doi.org/10.1007/s00125-013-2913-1
- Turpin, S.M., Nicholls, H.T., Willmes, D.M., Mourier, A., Brodesser, S., Wunderlich, C.M., Mauer, J., Xu, E., Hammerschmidt, P., Brönneke, H.S., et al. (2014). Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. Cell Metab. 20, 678-686. https://doi.org/10.1016/j.cmet.2014.08.002
- Unger, R.H. (2003). Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol. Metab. 14, 398-403. https://doi.org/10.1016/j.tem.2003.09.008
- Ussher, J.R., Koves, T.R., Cadete, V.J.J., Zhang, L., Jaswal, J.S., Swyrd, S.J., Lopaschuk, D.G., Proctor, S.D., Keung, W., Muoio, D.M., et al. (2010). Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption. Diabetes 59, 2453-2464. https://doi.org/10.2337/db09-1293
- Verma, M.K., Yateesh, A.N., Neelima, K., Pawar, N., Sandhya, K., Poornima, J., Lakshmi, M.N., Yogeshwari, S., Pallavi, P.M., Oommen, A.M., et al. (2014). Inhibition of neutral sphingomyelinases in skeletal muscle attenuates fatty-acid induced defects in metabolism and stress. SpringerPlus 3, 255-212. https://doi.org/10.1186/2193-1801-3-255
- Wang, C.N., O'Brien, L., and Brindley, D.N. (1998). Effects of cell-permeable ceramides and tumor necrosis factor-alpha on insulin signaling and glucose uptake in 3T3-L1 adipocytes. Diabetes 47, 24-31. https://doi.org/10.2337/diab.47.1.24
- Wang, R., Ding, Q., De Assuncao, T.M., Mounajjed, T., Maiers, J.L., Dou, C., Cao, S., Yaqoob, U., Huebert, R.C., and Shah, V.H. (2017a). Hepatic stellate cell selective disruption of dynamin-2 GTPase increases murine fibrogenesis through up-regulation of sphingosine-1 phosphate-induced cell migration. Am. J. Pathol. 187, 134-145. https://doi.org/10.1016/j.ajpath.2016.09.001
- Wang, Y., Harashima, S.I., Liu, Y., Usui, R., and Inagaki, N. (2017b). Sphingosine kinase 1-interacting protein is a novel regulator of glucosestimulated insulin secretion. Sci. Rep. 7, 779. https://doi.org/10.1038/s41598-017-00900-7
- Watt, M.J., Barnett, A.C., Bruce, C.R., Schenk, S., Horowitz, J.F., and Hoy, A.J. (2012). Regulation of plasma ceramide levels with fatty acid oversupply: evidence that the liver detects and secretes de novo synthesised ceramide. Diabetologia 55, 2741-2746. https://doi.org/10.1007/s00125-012-2649-3
- Xia, J.Y., Holland, W.L., Kusminski, C.M., Sun, K., Sharma, A.X., Pearson, M.J., Sifuentes, A.J., McDonald, J.G., Gordillo, R., and Scherer, P.E. (2015). Targeted induction of ceramide degradation leads to improved systemic metabolism and reduced hepatic steatosis. Cell Metab. 22, 266-278. https://doi.org/10.1016/j.cmet.2015.06.007
- Xiu, L., Chang, N., Yang, L., Liu, X., Yang, L., Ge, J., and Li, L. (2015). Intracellular sphingosine 1-phosphate contributes to collagen expression of hepatic myofibroblasts in human liver fibrosis independent of its receptors. Am. J. Pathol. 185, 387-398. https://doi.org/10.1016/j.ajpath.2014.09.023
- Xu, W., Lu, C., Zhang, F., Shao, J., and Zheng, S. (2016). Dihydroartemisinin restricts hepatic stellate cell contraction via an FXR-S1PR2-dependent mechanism. IUBMB Life 68, 376-387. https://doi.org/10.1002/iub.1492
- Yamashita, T., Hashiramoto, A., Haluzik, M., Mizukami, H., Beck, S., Norton, A., Kono, M., Tsuji, S., Daniotti, J.L., Werth, N., et al. (2003). Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proc. Natl. Acad. Sci. U. S. A. 100, 3445-3449. https://doi.org/10.1073/pnas.0635898100
- Yang, G., Badeanlou, L., Bielawski, J., Roberts, A.J., Hannun, Y.A., and Samad, F. (2009). Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. Am. J. Physiol. Endocrinol. Metab. 297, E211-E224. https://doi.org/10.1152/ajpendo.91014.2008
- Yang, L., Chang, N., Liu, X., Han, Z., Zhu, T., Li, C., Yang, L., and Li, L. (2012). Bone marrow-derived mesenchymal stem cells differentiate to hepatic myofibroblasts by transforming growth factor-beta1 via sphingosine kinase/sphingosine 1-phosphate (S1P)/S1P receptor axis. Am. J. Pathol. 181, 85-97. https://doi.org/10.1016/j.ajpath.2012.03.014
- Yang, L., Han, Z., Tian, L., Mai, P., Zhang, Y., Wang, L., and Li, L. (2015). Sphingosine 1-phosphate receptor 2 and 3 mediate bone marrowderived monocyte/macrophage motility in cholestatic liver injury in mice. Sci. Rep. 5, 13423. https://doi.org/10.1038/srep13423
- Yang, L., Yue, S., Yang, L., Liu, X., Han, Z., Zhang, Y., and Li, L. (2013). Sphingosine kinase/sphingosine 1-phosphate (S1P)/S1P receptor axis is involved in liver fibrosis-associated angiogenesis. J. Hepatol. 59, 114-123. https://doi.org/10.1016/j.jhep.2013.02.021
- Yano, M., Watanabe, K., Yamamoto, T., Ikeda, K., Senokuchi, T., Lu, M., Kadomatsu, T., Tsukano, H., Ikawa, M., Okabe, M., et al. (2011). Mitochondrial dysfunction and increased reactive oxygen species impair insulin secretion in sphingomyelin synthase 1-null mice. J. Biol. Chem. 286, 3992-4002. https://doi.org/10.1074/jbc.M110.179176
- Ying, W., Riopel, M., Bandyopadhyay, G., Dong, Y., Birmingham, A., Seo, J.B., Ofrecio, J.M., Wollam, J., Hernandez-Carretero, A., Fu, W., et al. (2017). Adipose tissue macrophage-derived exosomal miRNAs can modulate in vivo and in vitro insulin sensitivity. Cell 171, 372-384.e12. https://doi.org/10.1016/j.cell.2017.08.035
- Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L., and Wymer, M. (2016). Global epidemiology of nonalcoholic fatty liver disease-Metaanalytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73-84. https://doi.org/10.1002/hep.28431
- Zhao, H., Przybylska, M., Wu, I.H., Zhang, J., Maniatis, P., Pacheco, J., Piepenhagen, P., Copeland, D., Arbeeny, C., Shayman, J.A., et al. (2009). Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice. Hepatology 50, 85-93. https://doi.org/10.1002/hep.22970
- Zhao, H., Przybylska, M., Wu, I.H., Zhang, J., Siegel, C., Komarnitsky, S., Yew, N.S., and Cheng, S.H. (2007). Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes 56, 1210-1218. https://doi.org/10.2337/db06-0719
- Zigdon, H., Kogot-Levin, A., Park, J.W., Goldschmidt, R., Kelly, S., Merrill, A.H., Scherz, A., Pewzner-Jung, Y., Saada, A., and Futerman, A.H. (2013). Ablation of ceramide synthase 2 causes chronic oxidative stress due to disruption of the mitochondrial respiratory chain. J. Biol. Chem. 288, 4947-4956. https://doi.org/10.1074/jbc.M112.402719
- Zinda, M.J., Vlahos, C.J., and Lai, M.T. (2001). Ceramide induces the dephosphorylation and inhibition of constitutively activated Akt in PTEN negative U87mg cells. Biochem. Biophys. Res. Commun. 280, 1107-1115. https://doi.org/10.1006/bbrc.2000.4248
Cited by
- Modulation of sphingosine 1‐phosphate by hepatobiliary cholesterol handling vol.34, pp.11, 2020, https://doi.org/10.1096/fj.202001397r
- Ca2+ Sensitivity of Anoctamin 6/TMEM16F Is Regulated by the Putative Ca2+-Binding Reservoir at the N-Terminal Domain vol.44, pp.2, 2020, https://doi.org/10.14348/molcells.2021.2203
- Lipid metabolism in cancer progression and therapeutic strategies vol.2, pp.1, 2020, https://doi.org/10.1002/mco2.27
- Deletion or inhibition of SphK1 mitigates fulminant hepatic failure by suppressing TNFα‐dependent inflammation and apoptosis vol.35, pp.3, 2021, https://doi.org/10.1096/fj.202002540r
- Advances in paediatric nonalcoholic fatty liver disease: Role of lipidomics vol.27, pp.25, 2020, https://doi.org/10.3748/wjg.v27.i25.3815
- Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets vol.11, pp.11, 2020, https://doi.org/10.3390/diagnostics11112053
- Time-Dependent Changes in Hepatic Sphingolipid Accumulation and PI3K/Akt/mTOR Signaling Pathway in a Rat Model of NAFLD vol.22, pp.22, 2021, https://doi.org/10.3390/ijms222212478